Ledipasvir & Sofosbuvir

BreastfeedingPediatric

FDA APPROVAL DATE: 10/10/2014

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, Carbamazepine, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Rosuvastatin, Simeprevir, St John's Wort, Tenofovir Disoproxil

PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk; contra-indicated in pregnancy when given with ribavirin

See also separate entry for sofosbuvir.

Our database has 57 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
HEMATOLOGIC
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ledipasvir & sofosbuvir in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric